Science News – Scientific Sessions 2022

Welcome to #AHA22 Science News!

This is where you will find in-depth interviews from investigators and AHA experts on the Tier 1 late-breaking clinical trials during Scientific Sessions 2022. Expect at-a-glance summaries, analysis, and more!

Here are some important links:

Monday was the final day of Scientific Sessions presentation, but it was by no means the least exciting. #AHA22 Program co-chair Amit Khera and Manesh Patel give us a recap.


Comparative Effectiveness of Torsemide versus Furosemide in Heart Failure: Primary Results of the TRANSFORM-HF Trial
Robert J Mentz | Duke University Hospital, Durham, North Carolina


Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of Cardiovascular Events in Patients With Hypertension
Areef Ishani | Minneapolis VA Health Care System, Minneapolis, Minnesota


A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of Cardiovascular Disease
Aruna D Pradhan, Brigham and Women's Hospital | Boston, Massachusetts


First-in-Human in vivo CRISPR/Cas9 Editing of the TTR Gene by NTLA-2001 in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Julian D Gillmore | University College of London, London, United Kingdom


A Randomized Trial of Intravenous Ferric Derisomaltose in Heart Failure With Reduced Ejection Fraction
Paul R Kalra | Portsmouth Hospital, University NHS Trust, Portsmouth, United Kingdom


Steroids to Reduce Systemic Inflammation After Infant Heart Surgery: The STRESS Trial
Kevin D Hill | Duke Pediatric and Adult Congenital Heart Center, Durham, North Carolina


Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Primary Results From the Multicenter, Randomized ECMO-CS Trial
Petr Ostadal, Na Homolce Hosp, Prague, Czech Republic


The Effect of Adapted Mindfulness Training in Participants With Elevated Office Blood Pressure: The Mindfulness-Based Blood Pressure Reduction (MB-BP) Randomized Clinical Trial
Eric B. Loucks | Brown University, Providence, Rhode Island


Empagliflozin and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: The EMPA-KIDNEY Trial
David Preiss | University of Oxford, Oxford, United Kingdom


Comparison of a Precision Care Strategy With Usual Testing to Guide Management of Stable Patients With Suspected Coronary Artery Disease: The Precise Randomized Trial
Pamela S Douglas | Duke University School of Medicine, Durham, North Carolina


Best Endovascular versus Best Surgical Therapy for Patients With Chronic Limb Threatening Ischemia (BEST-CLI) Trial: Clinical Results
Alik Farber | Boston Medical Center, Boston, Massachusetts

Best Endovascular versus Best Surgical Therapy for Patients With Chronic Limb Threatening Ischemia (BEST-CLI) Trial: Quality of Life Analyses
Matthew T Menard | Brigham and Women's Hospital, Boston, MA


Successful Post-Discharge of Heart Failure
Alexandre Mebazaa | University de Paris, Paris, France


Self-Administered Etripamil for Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis From the RAPID Study
James E Ip | Weill Cornell School of Medicine, New York, NY


Effect of Radiofrequency Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 6-Month Primary Results From the SPYRAL HTN-ON Med Expansion Randomized Trial
David E Kandzari | Piedmont Heart Institute, Atlanta, GA